Locally Advanced or Metastatic Breast Cancer Clinical Trial
Official title:
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant in Combination With Phesgo Versus Phesgo After Induction Therapy With Phesgo + Taxane in Patients With Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally-Advanced or Metastatic Breast Cancer
This Phase III, randomized, two-arm, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus Phesgo compared with Phesgo after induction therapy with Phesgo plus taxane in participants with human epidermal growth factor receptor 2 (HER2)-positive, estrogen receptor (ER)-positive advanced breast cancer (metastatic or locally advanced disease not amenable to curative treatment) who have not previously received a systemic non-hormonal anti-cancer therapy in the advanced setting.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05860465 -
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03781063 -
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
|
Phase 2 | |
| Recruiting |
NCT05054751 -
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
|
Phase 3 | |
| Completed |
NCT03027245 -
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy
|
||
| Not yet recruiting |
NCT05172518 -
Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT05430399 -
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
|
Phase 3 | |
| Terminated |
NCT00634088 -
Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT05403333 -
Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT03437083 -
A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants
|
||
| Recruiting |
NCT05744687 -
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT05212701 -
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer
|
Phase 2 |